SCHEMBL7115137

SCHEMBL7115137

N#Cc1ccccc1Sc1ccc(C(=O)N[C@@H]2C[C@H]3CC[C@@H]2N3)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPHX2 P34913 1/20 0.42
CHRNA7 P36544 1/20 0.40
LMNA P02545 3/20 0.38
POLB P06746 2/20 0.38
MAPT P10636 4/20 0.37
HPGD P15428 3/20 0.37
EZH2 Q15910 2/20 0.36
NPC1 O15118 1/20 0.36
RAB9A P51151 1/20 0.36
HTT P42858 2/20 0.35
NPSR1 Q6W5P4 1/20 0.35
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
DDB1 Q16531 1/20 0.35
CRBN Q96SW2 1/20 0.35
ALDH1A1 P00352 2/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
PRKCB P05771 1/20 0.35
PRKCA P17252 1/20 0.35
PRKCE Q02156 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7117999 0.85 CHRNA7 (0.42) EPHX2CHRNA7MAPTEZH2NPC1
SCHEMBL7125131 0.85 EPHX2 (0.49) EPHX2CHRNA7LMNAEZH2NPC1
SCHEMBL7117164 0.84 CHRNA7 (0.42) EPHX2CHRNA7MAPTEZH2
SCHEMBL7125311 0.84 CHRNA7 (0.42) EPHX2CHRNA7LMNAMAPTHPGD
SCHEMBL7127524 0.84 CHRNA7 (0.55) EPHX2CHRNA7HPGDEZH2NPC1
SCHEMBL7116417 0.82 SIRT1 (0.46) EPHX2CHRNA7MAPTEZH2
SCHEMBL7120626 0.82 CHRNA7 (0.40) EPHX2CHRNA7HPGDEZH2ALDH1A1
SCHEMBL7118012 0.82 EPHX2 (0.39) EPHX2CHRNA7LMNAEZH2NPC1
SCHEMBL7124828 0.82 CHRNA7 (0.40) CHRNA7EZH2KDM1A
SCHEMBL7223906 0.81 LMNA (0.36) EPHX2CHRNA7LMNAPOLBMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030069296-A1 Substituted-aryl 7-aza[2.2.1]bicycloheptanes for the treatment of disease PHARMACIA & UPJOHN COMPANY 2003-04-10 US claimed
US-20030069296-A1 Substituted-aryl 7-aza[2.2.1]bicycloheptanes for the treatment of disease PHARMACIA & UPJOHN COMPANY 2003-04-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030069296-A1 Substituted-aryl 7-aza[2.2.1]bicycloheptanes for the treatment of disease CYP7B1, UGT2B7, CYP1B1 EPHX2 194/4885CHRNA7 397/4885LMNA 3819/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.